EditorialThe surgery and surgeons of tomorrow in the treatment of cancer
Section snippets
Initial and continuing training and proficiency testing
Up until the 2017 reform of the 3rd cycle of medical studies [4], French surgeons could reinforce their knowledge of oncology by obtaining the cancerology DESC (diploma in specialized complementary studies) with a “surgery” option, or else could receive this diploma by means of a VAE (professional experience validation). The latter has disappeared and been replaced, at least on paper, by FST (transversal specialized training). This training is known as FST cancerology: medical cancer
Territorial allocation of surgical activity
Since 2006, as to avoid loss of opportunity for cancer patients according to their site of treatment, authorization for cancer surgery based on threshold of activity and gradation of care offer is required. In other words, cancer operations can only take place in establishments where they are authorized. From one establishment to another, there exists unequal allocation with regard to different cancers, some of which call for “heavy-duty” structures (intensive care, resuscitation…), whereas
Conclusion
Treatment of cancerous tumors has become multidisciplinary and necessitates a transversal approach from diagnosis through the end of treatment and the establishment of monitoring protocols. Management should be premised on:
- •
reassessment of the territorial allocation of cancer treatments according to their degree of complexity;
- •
revalorization of heavy-duty surgical procedures;
- •
high-quality RCPs involving surgery, especially when interventional techniques are under consideration.
Once he has agreed
Disclosure of interest
The author declares that he has no competing interest.
References (6)
Epithor
Rev Malad Resp
(2020)- et al.
New treatment strategies for non-metastatic rectal cancer
J Vis Surg
(2021) - et al.
Global demand for cancer surgery and an estimate of the optimal surgical and anaesthesia workforce between 2018 and 2040: a population-based modelling study
Lancet Oncol
(2021)
Cited by (2)
Recent Trends in Computer-aided Drug Design for Anti-cancer Drug Discovery
2023, Current Topics in Medicinal Chemistry